News

404

Siu Kit “Samuel” Lam, Ph.D.

Siu Kit “Samuel” Lam, Ph.D.

SENIOR VP OF SCIENCE AND RESEARCH
Dr. Siu Kit “Samuel” Lam received his Bachelor of Science degree in Molecular and Cellular Biology from Johns Hopkins University and his Ph.D. in Immunology from Washington University in St. Louis. He previously worked at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University studying the GM-CSF secreting whole cell tumor vaccine. Prior to joining Immunophotonics, he was a member of the Center of Human Immunotherapy and Immunomonitoring Center at Washington University Medical School. His research spans from the basic science of the interactions between tumors and the host’s immune system to the development of cancer immunotherapy. Since joining the company, he has also acquired a master’s degree in Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University which provides training on the unique business and regulatory aspect of biotech ventures. His primary role at Immunophotonics is to oversee the research and development of the company’s assets, especially in the assessment of their in vivo efficacy and to further the understanding of their mechanisms of action.

SENIOR VP OF SCIENCE AND RESEARCH
Dr. Siu Kit “Samuel” Lam received his Bachelor of Science degree in Molecular and Cellular Biology from Johns Hopkins University and his Ph.D. in Immunology from Washington University in St. Louis. He previously worked at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University studying the GM-CSF secreting whole cell tumor vaccine. Prior to joining Immunophotonics, he was a member of the Center of Human Immunotherapy and Immunomonitoring Center at Washington University Medical School. His research spans from the basic science of the interactions between tumors and the host’s immune system to the development of cancer immunotherapy. Since joining the company, he has also acquired a master’s degree in Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University which provides training on the unique business and regulatory aspect of biotech ventures. His primary role at Immunophotonics is to oversee the research and development of the company’s assets, especially in the assessment of their in vivo efficacy and to further the understanding of their mechanisms of action.

Scroll to top